Cargando…
Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
Recent type 2 diabetes guidance from the UK’s National Institute for Health and Care Excellence (NICE) proposes offering SGLT2-inhibitor therapy to people with established atherosclerotic cardiovascular disease (ASCVD) or heart failure, and considering SGLT2-inhibitor therapy for those at high-risk...
Autores principales: | Young, Katherine G., Hopkins, Rhian, Shields, Beverley M., Thomas, Nicholas J., McGovern, Andrew P., Dennis, John M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623735/ https://www.ncbi.nlm.nih.gov/pubmed/37919773 http://dx.doi.org/10.1186/s12933-023-02032-x |
Ejemplares similares
-
Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020) -
SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020) -
The “discordant doppelganger dilemma”: SGLT2i mimics therapeutic carbohydrate restriction - food choice first over pharma?
por: Murray, Scott W., et al.
Publicado: (2021) -
Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure
por: Packer, Milton
Publicado: (2023) -
EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)